reports
Aeterna Zentaris Announces Departure of Vice President, Finance & Chie...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the “Company”) announced today the departure of the Company’s Vice President, Finance & Chief Accounting Officer, Geneviéve Lemaire, effective on or before September 30, 2017. The Company is currently reviewing its resource requirements with respect to its finance department and has commenced a search for Ms. Lemaire's replacement as principal financial officer. The Company thanks Ms. Lemaire for her contributions and wishes her ...
Aeterna Zentaris Engages Advisors and Provides Update to Shareholders
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), announced today that the special committee of independent directors (the “Strategic Review Committee”) has engaged a consulting firm and a financial advisor to assist in its efforts. As previously announced, the Strategic Review Committee has been tasked to consider and evaluate various strategic and financing alternatives available to the Company to maximize shareholder value, including continuing to execute on its existing bu...
- MarketLine Department
Aeterna Zentaris Announces Election of Directors at 2017 Shareholders'...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today announced the results of the vote on directors held at its 2017 annual meeting of shareholders held earlier today on May 9, 2017. Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxi...
Aeterna Zentaris to Announce First Quarter 2017 Financial and Operatin...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the “Company”) will announce its first quarter 2017 financial and operating results after market close on Monday, May 8, 2017. The Company will host a conference call and webcast to discuss these results on Tuesday, May 9, 2017 at 8:30 a.m. Eastern Time. Participants may access the live webcast via the Company’s website at www.aezsinc.com, or by telephone using the following number: 201-689-8029, Confirmation #13658332. A replay of the webcas...
Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptr...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the “Company”) today announced that the ZoptEC Phase 3 clinical study of Zoptrex™ (zoptarelin doxorubicin) in women with locally advanced, recurrent or metastatic endometrial cancer did not achieve its primary endpoint of demonstrating a statistically significant increase in the median period of overall survival of patients treated with Zoptrex™ as compared to patients treated with doxorubicin. Dr. Richard Sachse, the Company’s Chief Scientifi...
Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Cl...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”) will announce the top-line results of the ZoptEC Phase 3 clinical study of Zoptrex™ (zoptarelin doxorubicin) in women with locally advanced, recurrent or metastatic endometrial cancer prior to the commencement of trading on Monday, May 1, 2017. Conference Call The Company will host a conference call to discuss the results of the ZoptEC Phase 3 clinical study of Zoptrex™ on Monday, May 1, 2017, at 8:30 AM, Easte...
Aeterna Zentaris Mails Management Information Circular in Connection w...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”) today announced that it has mailed a Notice of Meeting and Management Information Circular (the “Meeting Materials”) to the shareholders of record as of March 20, 2017 in connection with its Annual Meeting of shareholders (the “Meeting”) to be held at the offices of Norton Rose Fulbright Canada, 1 Place Ville-Marie, Suite 2500, in Montreal, Canada on Tuesday, May 9, 2017 at 10:00 a.m. (Eastern Time). The Meeting M...
Aeterna Zentaris Intends to File NDA with Respect to Macrilenâ„¢ in Th...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”) today announced that, following its meeting with the U.S. Food and Drug Administration (the “FDA” or the “Agency”) on March 29, 2017, the Company intends to file a new drug application (“NDA”) seeking approval of Macrilen™ (macimorelin) for the evaluation of growth hormone deficiency in adults (“AGHD”). Commenting on the meeting, Dr. Richard Sachse, the Company’s Chief Scientific Officer, stated, “During our meeting with the F...
Aeterna Zentaris Announces At the Market Issuance Program
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS): All dollar amounts are stated in US$ Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the “Company”) announced today that it has commenced a new “at-the-market” offering pursuant to its existing At Market Issuance (“ATM”) Sales Agreement, dated April 1, 2016, with H.C. Wainwright & Co., LLC (the “Sales Agent”), under which the Company may, at its discretion, from time to time during the term of the ATM Sales Agreement, sell up to a max...
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial a...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology, today reported financial and operating results for the fourth quarter and year ended December 31, 2016. Commenting on recent key developments, David A. Dodd, President and Chief Executive Officer of the Company, stated, “During the fourth quarter and the first few weeks of 2017, we made substantial p...
Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pe...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the “Company”) announced today that the Pediatric Committee (“PDCO”) of the European Medicines Agency (“EMA”) agreed to the Company’s Pediatric Investigation Plan (“PIP”) for Macrilen™ and agreed that the Company may defer conducting the PIP until after it files a Marketing Authorization Application (“MAA”) seeking marketing authorization for the use of Macrilen™ for the evaluation of adult growth hormone deficiency. As part of the regulatory...
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financi...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”) will announce its fourth quarter and full-year 2016 financial and operating results after market close on Wednesday, March 15, 2017. The Company will host a conference call and webcast to discuss these results on Thursday, March 16, 2017 at 8:30 a.m. Eastern Time. Participants may access the live webcast via the Company's website at www.aezsinc.com, or by telephone using the following number: 201-689-8029, Confirmation # 13653...
Aeterna Zentaris Announces Presentation Regarding Macrilenâ„¢ at 99th ...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the “Company”) today announced that Jose M. Garcia, M.D., Ph.D., an Associate Professor of Medicine at the Puget Sound Veterans Administration Hospital and the University of Washington, will present an abstract entitled “Validation of Macimorelin as a Diagnostic Test for Adult Growth Hormone Deficiency (AGHD): A Phase 3 Study in Comparison with the Insulin Tolerance Test (ITT)” from 1:00 pm through 3:00 pm E.T. on Sunday, April 1, 2017 at the 99th Annu...
Aeterna Zentaris Announces Zoptrexâ„¢ Presentation in Prostate Cancer ...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the “Company”) today announced that a poster entitled, “A phase II trial of zoptarelin doxorubicin in castration-and taxane-resistant prostate cancer”, will be presented during the 2017 Genitourinary Cancers Symposium’s “Translating Research to Value-based and Patient-centric Care” by lead investigator, and co-author of the presentation, Jacek Pinski, MD, PhD, USC Norris Comprehensive Cancer Center, in Orlando, Florida on Thursday, February 16, 2017 at...
Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrile...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) for the evaluation of growth hormone deficiency in adults (“AGHD”), using the insulin tolerance test (the “ITT”) as a comparator, it concluded that Macrilen™ demonstrated performance supportive of achieving registration with the U.S. Food and Drug Administration (the “FDA”). The FDA has agreed t...
Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth & Heal...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”), announced today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 9:30 AM EST. President and Chief Executive Officer, Mr. David A. Dodd will be presenting an updated overview of the Company, as well as meeting with investors. Participants may access the live webcast via the Company’s website at www.aezsinc.com. A replay of the webcast will also be available on the...
Aeterna Zentaris to Present at the 2017 BIO CEO and Investor Conferenc...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that it will be presenting at the 2017 BIO CEO & Investor Conference on Monday, February 13 at 8:00 AM EST in New York City. President and Chief Executive Officer, Mr. David A. Dodd will be presenting an updated Company overview, as well as meeting with investors. Participants may access the live webcast via the Company's website at www.aezsinc.com. A replay of the webcast will also be available on the Company’s...
Aeterna Zentaris Announces Completion of Zoptrexâ„¢ Pivotal Phase 3 Cl...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced the occurrence of the 384th death in the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with Zoptrex™ (zoptarelin doxorubicin) in women with advanced, recurrent or metastatic endometrial cancer, representing the clinical endpoint of the study. The Company currently expects to lock the clinical database and to report top-line results in April 2017. Zoptrex™ is the Company’s proposed tradename ...
Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Tr...
CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) failed to achieve its objective of validating a single oral dose of macimorelin for the evaluation of growth hormone deficiency in adults (“AGHD”), using the insulin tolerance test (the “ITT”) as a comparator. The Company is evaluating the outcome of the trial and will determine in the near future whether it will continue with the development of Macr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.